ArticleNature communications2024
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Pooled it
- Prognostic value of baseline circulating tumor DNA levels in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).Prostate cancer and prostatic diseases · 2025Guideline
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Inter- and intra-quartile comparison of multi-tracer PET/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a "stepped care" model for individualized precision theranostics through AI/ML.European journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors.International journal of molecular sciences · 2026Article
- Liquid biopsy: a new window on the BRCA genes.ESMO open · 2026Review
- Analysis of the Correlation Between Circulating Cell-Free DNA (CfDNA) Levels and Serious Abnormal Sperm Parameters.Current issues in molecular biology · 2026Article
- Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).The journal of liquid biopsy · 2026Article
- A decision-oriented framework for genomic testing across the prostate cancer continuum.Cancer genetics · 2026Review
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Plasma circulating tumor deoxyribonucleic acid methylation enables noninvasive disease stratification beyond prostate-specific antigen in prostate cancer.Prostate international · 2026Article
- Circulating Tumor Function: A Systems Biology Framework for Liquid Biopsy in Genitourinary Cancers.Genes · 2026Review
- Circulating tumour cells as a window into lethality in prostate cancer.Nature reviews. Urology · 2026Review
- Cross-cohort projection of clinically anchored latent risk enables multi-omics interpretation without refitting.Briefings in bioinformatics · 2026Article
- Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.British journal of cancer · 2026Article
- Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England.British journal of cancer · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 6 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized multicentre phase II trials and a prospective province-wide blood biobanking program. ctDNA% correlates with serum and radiographic metrics of disease burden and is highest in patients with liver metastases. ctDNA% strongly predicts overall survival, progression-free survival, and treatment response independent of therapeutic context and outperformed established prognostic clinical factors. Recognizing that ctDNA-based biomarker genotyping is limited by low ctDNA% in some patients, we leverage the relationship between clinical prognostic factors and ctDNA% to develop a clinically-interpretable machine-learning tool that predicts whether a patient has sufficient ctDNA% for informative ctDNA genotyping (available online: https://www.ctDNA.org ). Our results affirm ctDNA% as an actionable tool for patient risk stratification and provide a practical framework for optimized biomarker testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.